5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures. by Suwanawiboon, Bundarika & Sumida, Kenneth N. M.
5-Azacitidine:
An Alternative TIeatment of Myelodysplastic
Syndromes in Patient with Refractory Response
to Hematopoletic Growth Factor
A Case Report and Review of Literatures
* ormerOdi.oai Res!dent, John
A. Burns School of Medicine,
Universit of Hawah, Currenty
Second Yew Fehowin
S5O:f rO/ccSr 0
Medcine :J..fl A. Bums School
of Medicine, Univershy of
Hasaii. Associate Progarn
Director P intearated Medicine
uaw0 rem- 0 Vec uS
0 KuaK
Monolu!,u. H
‘ 0
nOPS- uC’O
Abstract
Myeiodyspastic Syndrome 1MicS comprises a taut
erogeneous group of clonal hemopathies defived
from an abnormality atfooting a mut/potent hemato
potetic stem cell and charactetized by maturation
detects resulting rnerrecrive nerraroruo,es/s. S rnosr
rrequentrv omjrs in elderly pahents. L)espiie i’rSS
:estrng nsrr’erous agents ri natrersn’tU AIDS au
srigs drug has yet emerged as the accented stan
dard of treatment. Most MDS patients, due to the/rage
and no morbdtv. are not eligible for allogenerc he
matopoietic stern cell tratrso/antation; the only estab
ished curarve regimen. The effect of available ‘in
cage-seen/fin oronth hactors 5 ‘looSed to ‘mcroue
merit single lineages and has not resettng rn roe
survival benefit iSeatment with low dose Ara-C Is
disappointing in regard to response rate or duration,
No benefit has beer? demonstrated in different/at/on
a s ,,) ic er )s, ia D
aents Ve report a case of a raafient ;wth hansfus/zoo
aencride’u MDS who cas nor a canddare 1urr anoqe
ne/c stem CCI! Lranspiantaton or cytotozic cocoon
beraf ono a so railed to resoonse to e rope/c if
support buY hada favorable response to .5-azacitidine.
His etood trarurfision requir’erncnt reduced siriii
coo e api ith 5 am in Ir c ar 5
azacitidine appears to be a promising alternative
therapy for paiii.rnt with refractory anema s:econdany
Introduction
Myelodysplastic Syndrome(MDS, comprisesaheter
ogenous group of clonal hemopathies derived from an
abnormality affecting a multipotent hematopoietic
stem cell. MDS is characterized i-v the maturation
defects resulting in the ineffective hernatopciiesis and
various combinations ofcvtopenia. includinu. t not
limited to anemia, leukopenia, and throinhocytope
nia*4 It most frequently affects the elderly patients,
with greater than 80% of patients being older than 90
years of ace. Inthe population beyond 70 rears of age,
the incidence of MDS is approximately 22-45 per
10.000 population, indicating MDS is as prevalent as
the other most common hematologic malignancies of
the aged.’i Despite trials testing numerous agents 10
patients with MDS. no single drug has ret emerged as
accepted standard of treatment. Most MDS patients.
due to their age and co morbidity, are not eligible for
allogeneic hematopoietic stem cell transplantation,
the only’ established curative regimen. The effect ofthe
a ailable recombinant lineage—spectfic heniatoooienc
growth factors are limited to the impro\ ement of onis
single lineages and have not resulted in the survival
benefit. The treatment option of io close Ara-Q is
disappointing in regard to either survival or transfor
mation to AML.7 There has been no benefit demon
strated for differentiation inducers sum as retlnoti
attd vitamin D3. as the single agent theraps . ‘ We
describe a patient with transfusion dependent \IDS
who failed hematopoietic growth factor lerythropoi
e.ti.ni. but has- had a favorable respon.se to 5-azr.citi.drine
resulting in the significant improvement of anemia
and rhromb*cYtop.enia as well as the remarkable re
rtuutir*n of blood transtusron reciurement.
Report of a Case
A 75 year-old man. presented to the hem.at.ology cliflc,
referred b•v his primary care rihys.i.cian for •tbrther
evaiuation of anemia. i-fe was noted to have a mild
anemia i-lb I 1 .1) is dl and Hct 355 ‘xith MQV 92.6
during his annual physical examination. Patient was
asvmptomatic at the time. There was no history of
blood loss, peptic ulcer disease. bowel habit change,
weight lOss or ulcerogenic drug use. His pertinent
medical history consisted of hvpercholesterolemia
treated with a lipid lowering acent, childhood asthma
and chronic nasal allergy. His physical examination
was unremarkable and without lymphadenopathy or
organomegalv. Other laboratory findings included a
mild leukopema \ BC 2.900 mm ith a normal
/bnuiarzka
IU 11/boon .111)
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platelet count. The peripheral blood smear revealed
normal red blood cell, white blood cells and platelet
morpholouv. The CRC drawn seven rears earlier
revealed a Rh and Rct 16.2 gdl and 4b.0r4, respec
tively. Further laboratory work up, including hon
study, Folate, Vitamin B 12 level, and TSR. were all
normal ..\tt he time, clinical observation and regular
CRC monitoring were recommended. civen that he
was clinically stable without anemia or leukopenia—
related symptoms.The follow up Rh and Ret re
mained stable ( Rb and Ret were in the range of 12.6-
13.8 dl and Hct 38.3-40.6 0/s, respectiveivi without
any treatment until three years later when the patient
was noted to have a further decline in Rb and Ret Rb
a dl san Lt 2u e \i( -I ijdition (BC
wasalso remarkable forworsening,leukopenia(WBC
2,400/mm with normal differential count The pe
ripheral blood smear showed 2— anisocvtosis with
increased macroe Tes, The bone marrow asmranon
and biopsy was then performed. The pathology report
included 3%’ cellularutvwithpatch marrow fibrosis.
The ervthroidprecursors revealed normobiastic eryth
roid hvpoplasia with adequate stainable iron. There
was an evidence of left-shifted granulopoiesis with
delayed maturation and dysmegakam’opoiesis. The
et ndin Ntion,j\ rel \IDS refrn is
anemia RA) subtype. Hematopoietic Growth Factor,
(erythropoietin , initially at 10,000 units given subcu
taneously thrice weekly was then begun and contin
ued for four ‘ths The ervrhropoienn dose a as
subsequently increased to 20,000 units given twice
weekir for another four months crue to no Si enlficlmnl
reductonin packed red blood cell transfusion requirm
ment o.r i.m,provement of iTh/Hct, which dropped to as
low as 5.8 g/dl and 1.7.2%, respectively. During the
e a — an IL ‘e 1 rt UI i fl
bocvtoaenia w oh latelet counts raneedheeween
-
“L Ct CLI U 1
row examination was rerformed. The findings re
vealed hypoceilularity, d.vshematopoiesis, progres
or marrow fibrosis, bicyto,renia and persistent
OiOSttC rrnirs
fcr’nlat..’n. 000sisrc’irr ‘o 00 ,‘sisofMDS.
Ar th.is mm, re carRot’ .i.
lttecte fo the rean meordal o MD S1nc e
was oomed not a oe a anon anodluatU for more
aggressive therapy, including the allogeneic stem cell
n’ansplantatuon. alternative treatment with investica—
tional anent: s—azacitidine was coils idered. Fi e—
azacitidine was started under tile compassionate re
lease protocol from the NIH. The treatment schedule
consists of 75 mg/m2of5-azacitidine given subcuta
neously everyday for 7 days per c dc as an outpatient
treatment. The treatment course was repeated every
twentv—euellm days for six cycles and an additional two
cycles with 5t,fa dose-reduction were given after the
completion of the sixth cycle. Following the third
course of5—azacitidine. a remarkable improvement in
tile pancvtopenia. particularly tile anemia and throm—
hocttopenia. was demonstrated. The Rh rose to as
high as 11.8 it dl with Ret to 34.2%, a major progress
comparing with that observed during tile erythropoi-’
etin therapv.The requirement for packed red blood
cell transfusion also declined dramatically and corre
lated with tile response in the Rh and Ret. Row ever,
the most notable laboratory response was seeil in the
platelet count, which displayed i nthe range of I 04,bOO-
536,000x’mnd. These hematologic responses to the
treatment has e heeil maintained for months after the
discontinuation otthe medication. Durine the course
ofthe treatment, the reported adverse effects included
mild leukopenia without neurropenia \\‘BC I
3,6U0!mm- which resolved prior to the next acinlin—
istration of 5-azacitidinet mild nausea and vomiting
relievedwith anuenlencs. Tile liverand renal function
rests remained normal throuehout the course of the
tilerap’.
Discussion
To date there are no curative therapeutic options for
patients with MDS. a ith the exceptuon of intensive
ellemotherany witil alloeeneic stem—cell transplanta
tion, available to a minority of voting atuents. ne
data tronl clinical trials ensploved intensive cllemo
therapy with autologous hetnatopoietic stem cell sup
port islitnited and its value remains to he proven. The
response duration is often short ‘mud the relapse rate is
inca.” There is no .survrval benefit seen in a ranuonl—
ized trial camnarirre ow-nose eviarahine wurir sup
portive care alone.’ Topoisomerase I Inhibitors have
ainecl interest but they’are report.ed with the substan
tial toxicity. Cell-differentiation therapy with either
re’onoucls ,Irvitaninl D3 analoes fins r’ieLled rusan—
1 I 01
— tJTllL 11” ,, “0,, C ‘c.
.neaee-srecr oro\vtn tacrors. such .is etvtilropo!
eOn, 0-C SF, or GM-QSF has pre.vided only tile lim
ited improvement of the single lineages and. has not
resulted in tile survrval hen.efit , Unfortunately, the
0100 out ci Oaiietits to 01 Ds are eroerir
‘l
precmri.e t nec’ tront t— ocr, c-iran ia rite more
cive therapy, especially the aliogeneic sten cclii trans
plo tatian m ttlese panerts 01e ante! therapeutic
approachisneeded and should he aimed at eradication
or suppression of the abnornlal clone or induction ot’
cell differentiation at’ the pre—nlalirnant clone,
iive-Azacitidinetazaciticline the ring analogue of
the pyrimidile nucleoside cytidine, first synthesized
in I Q64 by Sorm and co-worker, has been clinically
de\’eloped based Oil tile stron ill vitro and n vivo
antileukenlic actIvity at cvtoioxic concentrations. ann
ditferenuation—inducing potential a-t lower concetitra—
tions in cell line nlodels of hematopoietic and non
hemato-poietic lineages c’”' The mechanism at letion
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is believed to be distinct from those of other pvrimi
dine annmetabolites, including Ara-C’. suggested by
the lack of severe bone marrow hypoplasia preceding
the hematologic reponses to low-dose azacitidine in
myelodvsplasia, Following its phosphorylation to
monophosphates. 5-azacitidine is incorporated into
newly synthesized DNA resulting in hvpomethvlated
DNA strand synthesis.7 As recently reviewed. cv
tosine hvpermethvlation of numerous genes i mpor—
tant in orderly cell proliferation and maturation is
frequent in primary neoplasia and tumor cell lines.
Therefore. the application of pharmacologic inhibi
tors of DNA methvlation provides a theoretically
rational approach to regress these epigenetic changes
in the malitinant clone and re—establishing the
antiproliferative and possibly differentiation-induc
ing signals silenced by hvpermethylation. ‘ In KIDS,
the disturbed maturation of the morphologically dys
plastic hematopoietic cells is thought to reflect a
partial block in their differentiation with proliferation
ofpreleukemic mvelohlasts. providing a rationale for
clinical trials of DNA methvlation inhibitors. Five
azacitidine has shown activity in approximately 50%
of MDS patients in several uncontrolled studies pub
lished since 1984, with two phase-Il trials and a single
phase-Ill study, initiated by the Cancer and Leukemia
Group B CALGB in 1984. 1989 and 1994. respec
tivelv,” In the CALGB 8421 trial, a continuous infu
sion of azacitidine 75 mg. rn for seven days, repeated
every 28 days, resulted in a 49% response rate with
12% complete remission (CR5), 25% partial remis
sion (PR5) and 12% hematological improvement
HI5 ).‘ In addition, the complete elimination of all
transfusion requirements occurred in 82% of the Pa
tients, bile another 1 8% had a greater than 50%
reduction in the number of units required per month.
In the CALGB 8921 trial reported by Silverman t,aI,
azacitidine given at the same total dose was adminis
tered by daily subcutaneous bolus injection, thus
allo ing for outpatient treatment: This resulted in a
53% overall response rate I 2% CR. 15% PR and 27%
HI . The median time to response as 4.5 treatment
courses. The median response duratton was 17.3
months. These two clinical trials were performed in
high-risk MDS patients, However, there was a rela
tively lower rate of trilineage response with subcuta
neous administration of azacitidine 27% VS 37%
Rugo jjiI also treated 92 pattents most of them with
ht,0 rtk \I u’’ \vre LI v lied retriLtor\
anemia with excess hlasts;RAEB in transformation or
chronic myelomonocytic leukemia or secondary
AML, with the same outpatient schedule of 75mg m2
D given subcutaneously for 7 days. repeated every
twent -eight clays for six c des. In a retrospecti e
analysts, they reported a 61% response rate 13” CR
and I 9°. PR . Two patients with complete hemato—
logical response also hadacvtogenetic remission. The
significant improvement in qualit of life’aid well
being in patients treated with azacitidine was demon
strated in a randomized phase-Ill study done by
CALGB in 1998, using the identical dose and subcu
taneous route.’7 In this study, response rate. survival
and time to progression to AML in treated patIents
were compared with a patient group assigned to a
four-month observation period. Study desiL’n allowed
cross over to the treatment arm after 4 months in those
with disease progression. The response rate in the
treatment group was 63% and the probability of
transformation to AML was 11%. compared with a
31% transformation tate in patients on observation.
which was statistically significant P0.003. The
common adverse effects are Cl toxicity, which is
usually mild, including nausea and/or vomiting, fol—
lowed by diarrhea, Other side effects were less fre
quent and included elevation of hepatic transaminase
enzymes and confusion.
Conclusion
5-azacitidine has demonstrated significant activity in
ameliorating or even temporarily correcting both the
deficits in peripheral blood counts of all three lineages
and the pre-leukemic blast excess in high-risk MDS.
This combination of activities. the convenient outpa
tient treatment schedule as well as the mild adverse
reaction profile makes this drug distinctively promis
ing. In elderly patients with MDS who frequently
have significant co-morhidities, this low-intensive,
low toxicity therapy may be an optimal alternative.
‘CR Complete response was defined as full normalization of
all three peripheral blood counts and less than 5% myelo
blasts in bone marrow
‘PR Partial response was defined as achieving a greater
than 50% restoration of the deficit from normal in each of the
three peripheral blood counts and absence of myeloblasts in
peripheral blood, the elimination of transfusion requirements,
and decrease in percentage of myeloblasts in the bone
marrow by 50%
HI’: Hematological improvement: greater than 50% restora
tion in the deficit from normal in either red cell, white cell. or
platelet counts andf or at least 50% decrease in the transfu
sion requirement from baseline.
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Classified Notices
To place a classified notice:
HMA members—Please send a signed and type
written ad to the HMA office. As a benefit ot member
ship. HMA members may place aco-mplimentarv one
time classified ad in HMJ as space N available.
Nonmembers,—Please call 536-7702 for a non-
member form. Rates are $1.50 a word with a minimum
of 20 words or $30. Not commissionable. Payment
must accompany written order,
Units for Sale
AIEA MEDICAL BUILDING 2 ,JOLTS AVA]LABE
SALE UnrI #205 offered at $102,000 Co rESBsa ft
#206 offered at 6’ ‘3000 LH 1698sq.ft.) Buy each un-rI senor
rate]y ortogetne- Oar. Vnce Vanderatroorn. RAtormore rYc
and ahowings cP 778-0065/947-8112.
Seeking Position
ANESTHESIOLOGIST — LOOK1NG FOR POSITION. Soc
ciaHnterestPa]nMananement.25yearsexperienceinFann’Iy
Medicine 5 years enperi900e in Anesthesroiogy. Pn-ET
Inquir]es by c-marl at dkosre@yaboo.com.au,
Aloha Laboratories, Inc.
I’hen results count
A CAP accredited laboratory
specializing in Anatomic
Pathology
Quality and Service
David M. Am berger. M.D.
Laboratory Director
Phone: (808) 832-6600
Fax: (808) 848-0663
F—Mail: rcsults’vi alohalabs.coni
hItp:i/s t.a1oha1ahs.coinIn cii 111,2 SiflOlitoril ìl rim’ ‘ecu iii tire I l:imajj Medical J,’rurnal,
1” piaec a a’laSsitied ad call 536—7702.
23
